Current influenza vaccination using needle injections requires annual updates of vaccine strains and imposes a tremendous burden on healthcare workers worldwide. Oral vaccination, which is a very convenient and safe route for vaccination, could improve the prevention of mucosal infection by influenza viruses. However, it is a challenging problem to stabilize the vaccine antigens in the harsh environment of stomach and to target them to the immune system of intestines. Our preliminary studies provide evidence that inactivated influenza vaccines can provide heterosubtypic cross protection if their immunogenicity is enhanced, and that oral vaccination can confer protective immunity. In our quest to advance to the next generation of vaccines using novel nanotechnology formulation, we propose to encapsulate influenza vaccines into stabilized small beadlike particles containing microspheres and nanospheres for oral vaccine delivery. Oral vaccines to be tested include the currently licensed forms of inactivated and live vaccines against the 2009 pandemic influenza virus. The main focus in aim 1 will be to encapsulate the influenza vaccines with an acid resistant material to stabilize vaccine antigens in the gastric environment, and the ligands, strategically targeting them to the intestinal immune system of Peyer s patches and M cells.
In Aim 2, we will determine the breadth of cross protective efficacy with promising influenza oral vaccine candidates using the human H1N1 isolate of the 2009 pandemic influenza virus, and heterologous and heterosubtypic influenza strains in a mouse model. In addition, we will evaluate the efficacy of oral vaccination in ferrets, which is a more relevant animal model for testing pre-clinical influenza vaccines for humans. It is expected that improved oral vaccination will provide protection against the strains including the 2009 H1N1 influenza virus, which would have significant implications for clinical applications and for improving the public health.

Public Health Relevance

Oral vaccination is a convenient and safe method for mass immunization. Development of an effective oral vaccination strategy will improve public health by preventing vaccine-preventable diseases such as influenza.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
High Priority, Short Term Project Award (R56)
Project #
7R56AI087782-02
Application #
8416159
Study Section
Vaccines Against Microbial Diseases (VMD)
Program Officer
Salomon, Rachelle
Project Start
2011-07-15
Project End
2013-06-30
Budget Start
2011-09-01
Budget End
2013-06-30
Support Year
2
Fiscal Year
2011
Total Cost
$417,740
Indirect Cost
Name
Georgia State University
Department
Type
Organized Research Units
DUNS #
837322494
City
Atlanta
State
GA
Country
United States
Zip Code
30302
Lee, Jong Seok; Lee, Yu-Na; Lee, Young-Tae et al. (2015) Ginseng protects against respiratory syncytial virus by modulating multiple immune cells and inhibiting viral replication. Nutrients 7:1021-36
Kim, Min-Chul; Lee, Yu-Na; Ko, Eun-Ju et al. (2014) Supplementation of influenza split vaccines with conserved M2 ectodomains overcomes strain specificity and provides long-term cross protection. Mol Ther 22:1364-1374
Choi, Hyo-Jick; Kim, Min-Chul; Kang, Sang-Moo et al. (2014) The osmotic stress response of split influenza vaccine particles in an acidic environment. Arch Pharm Res 37:1607-16
Kwon, Young-Man; Hwang, Hye Suk; Lee, Jong Seok et al. (2014) Maternal antibodies by passive immunization with formalin inactivated respiratory syncytial virus confer protection without vaccine-enhanced disease. Antiviral Res 104:1-6
O, Eunju; Ko, Eun-Ju; Kim, Min-Chul et al. (2014) Distinct B-cell populations contribute to vaccine antigen-specific antibody production in a transgenic mouse model. Immunology 142:624-35
Choi, Hyo-Jick; Bondy, Brian J; Yoo, Dae-Goon et al. (2013) Stability of whole inactivated influenza virus vaccine during coating onto metal microneedles. J Control Release 166:159-71
Kim, Min-Chul; Song, Jae-Min; O, Eunju et al. (2013) Virus-like particles containing multiple M2 extracellular domains confer improved cross-protection against various subtypes of influenza virus. Mol Ther 21:485-92
Park, Min-Kyung; Ngo, Vu; Kwon, Young-Man et al. (2013) Lactobacillus plantarum DK119 as a probiotic confers protection against influenza virus by modulating innate immunity. PLoS One 8:e75368
Kim, Yeu-Chun; Yoo, Dae-Goon; Compans, Richard W et al. (2013) Cross-protection by co-immunization with influenza hemagglutinin DNA and inactivated virus vaccine using coated microneedles. J Control Release 172:579-88
Kim, Min-Chul; Lee, Jong-Seok; Kwon, Young-Man et al. (2013) Multiple heterologous M2 extracellular domains presented on virus-like particles confer broader and stronger M2 immunity than live influenza A virus infection. Antiviral Res 99:328-35

Showing the most recent 10 out of 22 publications